Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Kazuhiko Shien

Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR-mutant Non-Small Cell Lung Cancer Cells

Molecular Cancer Research

English

Interaction of Cytokeratin 19 Head Domain and HER2 in the Cytoplasm Leads to Activation of HER2-Erk Pathway

Scientific Reports

Multidisciplinary

2016

English

Related publications

Mechanism Research of miR‐34a Regulates Axl in Non‐small‐cell Lung Cancer With Gefitinib‐acquired Resistance

English

The miR‑625‑3p/AXL Axis Induces Non‑T790M Acquired Resistance to EGFR‑TKI via Activation of the TGF‑β/Smad Pathway and EMT in EGFR‑mutant Non‑small Cell Lung Cancer

English

Newly Emergent Acquired EGFR Exon 18 G724S Mutation After Resistance of a T790M Specific EGFR Inhibitor Osimertinib in Non-Small-Cell Lung Cancer: A Case Report

OncoTargets and Therapy

Oncology

Pharmacology

2018

English

Cecal Volvulus as a Rare Complication of Osimertinib Dosed at 160 Mg in Patients With EGFR-Mutant Non-Small Cell Lung Cancer

Frontiers in Oncology

Cancer Research

Oncology

2020

English

P3.01-95 EGFR Genotype as a Predictor of Survival in EGFR Mutant Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

English

Inhibition of Casein Kinase 1 Alpha Prevents Acquired Drug Resistance to Erlotinib in EGFR-Mutant Non-Small Cell Lung Cancer

Cancer Research

Oncology

2015

English

Acquired EGFR C797S Mutation Mediates Resistance to AZD9291 in Non–small Cell Lung Cancer Harboring EGFR T790M

English

Osimertinib (AZD9291) Increases Radio‑sensitivity in EGFR T790M Non‑small Cell Lung Cancer

English

Overcoming T790M Mutant Small Cell Lung Cancer With the Third-Generation EGFR-TKI Osimertinib

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Kazuhiko Shien

Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR-mutant Non-Small Cell Lung Cancer Cells

Interaction of Cytokeratin 19 Head Domain and HER2 in the Cytoplasm Leads to Activation of HER2-Erk Pathway

Related publications

Mechanism Research of miR‐34a Regulates Axl in Non‐small‐cell Lung Cancer With Gefitinib‐acquired Resistance

The miR‑625‑3p/AXL Axis Induces Non‑T790M Acquired Resistance to EGFR‑TKI via Activation of the TGF‑β/Smad Pathway and EMT in EGFR‑mutant Non‑small Cell Lung Cancer

Newly Emergent Acquired EGFR Exon 18 G724S Mutation After Resistance of a T790M Specific EGFR Inhibitor Osimertinib in Non-Small-Cell Lung Cancer: A Case Report

Cecal Volvulus as a Rare Complication of Osimertinib Dosed at 160 Mg in Patients With EGFR-Mutant Non-Small Cell Lung Cancer

P3.01-95 EGFR Genotype as a Predictor of Survival in EGFR Mutant Non-Small Cell Lung Cancer

Inhibition of Casein Kinase 1 Alpha Prevents Acquired Drug Resistance to Erlotinib in EGFR-Mutant Non-Small Cell Lung Cancer

Acquired EGFR C797S Mutation Mediates Resistance to AZD9291 in Non–small Cell Lung Cancer Harboring EGFR T790M

Osimertinib (AZD9291) Increases Radio‑sensitivity in EGFR T790M Non‑small Cell Lung Cancer

Overcoming T790M Mutant Small Cell Lung Cancer With the Third-Generation EGFR-TKI Osimertinib